UPDATE: JMP Securities Downgrades PLx Pharma (PLXP) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities turn lower, as fragile yen remains on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
UPDATE: Oppenheimer Downgrades PLx Pharma (PLXP) to Perform
August 15, 2022 3:07 AM EDT(Updated - August 15, 2022 5:17 AM EDT)
Oppenheimer analyst Leland Gershell downgraded PLx Pharma (NASDAQ: PLXP) from Outperform to Perform.
The analyst comments "Implementation of a refined marketing plan notwithstanding, 2Q22 Vazalore net sales were $483K (-77% Q/Q) vs. $3.5M consensus estimate.... More
PLx Pharma (PLXP) Tops Q2 EPS by 4c
August 12, 2022 7:32 AM EDTPLx Pharma (NASDAQ: PLXP) reported Q2 EPS of ($0.52), $0.04 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $483 thousand versus the consensus estimate of $3.53 million.
For earnings history and earnings-related data on PLx Pharma (PLXP) click here.
... More
